Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.
Human immunodeficiency virus (HIV) reverse transcription can be notably affected by cellular activation, differentiation, and division. We hypothesized that changes in the cell cycle could also affect HIV susceptibility to nucleoside analogues, which compete with natural nucleotides for incorporation into viral DNA and inhibit viral replication through premature termination of reverse transcription. Proliferating HeLa-derived indicator cells were arrested in the S/G2 phase with etoposide, a topoisomerase II inhibitor, or in the G1/S phase with aphidicolin, a polymerase alpha inhibitor. Cell cycle arrest by both agents induced a remarkable decrease in HIV susceptibility to zidovudine (AZT). This decrease was seen both with a single-cycle infectivity assay and with a viral DNA quantitation assay, indicating that the effect of cell cycle arrest was exerted at the reverse transcription stage. The increase in the 50% inhibitory concentration (IC50) seen with arrested cells was strongest for AZT (23-fold) and stavudine (21-fold) but more modest for other drugs (lamivudine, 11-fold; dideoxyinosine, 7-fold; and nevirapine, 3-fold). In drug-resistant reverse transcriptase mutants, the increase in AZT IC50 (relative to that in dividing cells) was most prominent with a Q151M mutant and was comparable to the wild type in other drug-resistant mutants. Quantitation of intracellular pools of dTTP and AZT 5'-triphosphate (AZTTP) showed that etoposide treatment induced a significant increase in intracellular dTTP and consequently a decrease in AZTTP/dTTP ratios, suggesting that the decrease in viral susceptibility to AZT was caused by reduced incorporation of the analogue into nascent viral DNA. These results emphasize the importance of cellular proliferation and deoxynucleoside triphosphate metabolism in HIV susceptibility to nucleoside analogues and underscore the need to study the activities of drugs of this class with natural target cells under physiological conditions of activation and proliferation.
Wurtzer
Sebastien
S
Unité de Recherche Antivirale, Inserm U552, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France.
Compain
Séverine
S
Benech
Henri
H
Hance
Allan J
AJ
Clavel
François
F
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002453:Cell Cycle / Q000502:physiology*; D004247:DNA / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D006367:HeLa Cells; D006801:Humans; D007928:Lethal Dose 50; D009705:Nucleosides / Q000737:chemistry / Q000494:pharmacology*; D016196:S Phase / Q000502:physiology*; D015215:Zidovudine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D009705:Nucleosides; D015215:Zidovudine; D004247:DNA; D054303:HIV Reverse Transcriptase